PRAXIS PRECISION MEDICINES I (PRAX) Stock News
NASDAQ:PRAX - Nasdaq - US74006W2070 - Common Stock - Currency: USD
PRAX Latest News, Press Relases and Analysis
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines to Present at Two February Investor Conferences
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Praxis Precision Medicines to Present at Two February Investor Conferences
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 ...
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease...
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating...
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Mentions: IONS
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on...